Form 4: Relay Therapeutics CFO Thomas Catinazzo Sells Shares to Cover Tax Obligations

Relay Therapeutics' CFO, Thomas Catinazzo, sold shares of common stock on June 27, 2024, to cover income tax withholding obligations related to vesting restricted stock units.

Summary

• Thomas Catinazzo, the Chief Financial Officer of Relay Therapeutics, Inc., sold shares of the company's common stock on June 27, 2024.
• A total of 295 shares were sold at a price of $6.26 per share to cover income tax withholding obligations upon the vesting of 992 restricted stock units (RSUs).
• An additional 9,078 shares were sold at a weighted average price of $6.24, executed in multiple trades ranging from $6.12 to $6.32, pursuant to a Rule 10b5-1 trading plan adopted on February 15, 2024.
• Following these transactions, Catinazzo beneficially owns 330,430 shares of Relay Therapeutics common stock, including 304,929 shares underlying RSUs.

Sentiment

Score: 6

Explanation: The document is neutral. It simply reports stock sales by the CFO, which are partly for tax obligations and partly under a pre-arranged trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The sale of shares to cover tax obligations is a common practice and doesn't necessarily indicate a negative outlook.
• The additional sale was executed under a pre-arranged 10b5-1 trading plan, suggesting it was planned and not based on immediate market conditions.

Future Outlook

There are no explicit forward-looking statements in this document.

Industry Context

Insider transactions are routinely monitored and reported, providing transparency into the actions of company executives. Sales to cover tax obligations are common, while pre-planned sales under Rule 10b5-1 are designed to avoid accusations of trading on inside information.

Comparison to Industry Standards

• It is common for executives at publicly traded companies, including those in the biotechnology sector like Relay Therapeutics, to utilize 10b5-1 trading plans to diversify their holdings or manage tax liabilities.
• Comparable companies such as Amgen, Biogen, and Vertex Pharmaceuticals also see regular Form 4 filings related to stock sales by their executives.
• The size and frequency of these transactions are generally in line with industry norms for companies of Relay Therapeutics' size and stage of development.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sale does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates